Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 22 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 12 Sep 2019
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.

Ceftaroline: A 5th generation cephalosporin for the treatment of CAP and cSSTIs in the era of antimicrobial resistance

24 Jan 2019
Antimicrobial resistance has been recognized as a serious public health issue.
In an era of antimicrobial resistance, newer agents are urgently needed. Ceftaroline, a broad spectrum cephalosporin approved for the treatment of community-acquired pneumonia (CAP) and complicated skin and soft tissue infections (cSSTI) is a step forward towards addressing this need. MIMS Anti-Infectives interviewed Dr Asok Kurup, an infectious disease physician practising at the Mount Elizabeth Medical Centre in Singapore, to provide some insights into the role of ceftaroline for the treatment of these conditions.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 22 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 12 Sep 2019
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.